Cercainide

Drug Profile

Cercainide

Alternative Names: CRE 1087

Latest Information Update: 31 Mar 1995

Price : $50

At a glance

  • Originator Alter; Cermol
  • Class Class I antiarrhythmics
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 31 Mar 1995 Discontinued-II for Arrhythmias in Spain (IV)
  • 31 Mar 1995 Discontinued-II for Arrhythmias in Spain (PO)
  • 31 Mar 1995 Discontinued-II for Arrhythmias in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top